Artificial intelligence is reshaping the pharmaceutical and biotech industries by enabling smarter, faster, and more precise workflows. Among these advances, agentic AI workflows stand out for their ability to perform complex tasks autonomously, making them invaluable in drug discovery, clinical trials, and manufacturing. This article explores the top agentic AI workflows currently trending in pharma and biotech, highlighting their practical applications and impact. Robotic arm automating...

CiNTL Pharma B.V. Phase 2 clinical trials are where pharmaceutical development transitions from proof of concept to proof of value. They are also where a significant proportion of drug development budgets are consumed. The average cost of a Phase 2 trial ranges from $7 million to $20 million, depending on therapeutic area, patient population, and trial complexity. For many sponsors, Phase 2 is both the most critical and most financially exposed stage of development. AI-enabled clinical trial...

CiNTL Pharma B.V. Artificial intelligence has moved from the periphery of clinical research conversations to the center of regulatory policy. The European Medicines Agency has been among the most active regulators globally in developing frameworks for the use of AI in medicine development. But the critical question for sponsors and CROs is not whether the EMA has published guidance on AI. It is whether the agency truly believes in the need to adopt AI in clinical trials, or whether its...